Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | SUNMO: mosunetuzumab + polatuzumab vedotin vs R-GemOx in R/R aggressive NHL

Jason Westin • 16 Jun 2023
ICML 2023
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Gemcitabine Mosunetuzumab Oxaliplatin Polatuzumab vedotin Rituximab
SUNMO

Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the ongoing Phase III SUNMO trial, which is evaluating the safety of mosunetuzumab in combination with polatuzumab vedotin (M-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL; NCT05171647). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jason Westin

Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
1:41
Real-world efficacy of tafasitamab + lenalidomide in R/R DLBCL & the importance of patient selection
Jason Westin • 8 Sep 2023
2:05
Clinical guidance for the use of bispecific antibodies in NHL
Jason Westin • 8 Sep 2023
2:08
The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & more
Jason Westin • 8 Sep 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals